Skip to content

Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status

To Prospectively Evaluate the Potential for Simple, Effective Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00383500
Enrollment
75
Registered
2006-10-03
Start date
2005-05-31
Completion date
2009-09-30
Last updated
2017-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Lymphedema

Brief summary

To compare the effectiveness of usual treatments for lymphedema \[massage and elastic compression sleeve, instituted at-risk and before the development of swelling (lymphedema)\], compared to the use of a newly-marketed device, the Flexitouch, which electronically simulates the effect of massage upon lymph flow.

Detailed description

The current investigation is designed to prospectively evaluate the potential for simple, effective lymphedema prophylaxis in breast cancer survivors who show early evidence of high-risk status. There is growing evidence that the mechanisms of lymphatic repair after injury are mediated through lymphatic flow. Accordingly, this study assess if physical measures designed to prophylactically augment lymphatic flow after surgical interventions for breast cancer (eg, Flexitouch and manual lymphatic massage) will reduce the incidence of lymphatic stagnation, assessed as incidence of lymphedema, when compared to patients who receive conventional watch and wait interventions (observation). The specific aims of the study are 1. to prospectively assess the presence of newly developing lymphedema in each study subgroup through serial assessment of segmental interstitial fluid content by multiple frequency bioimpedance 2. to evaluate the preventive interventions in a prospective, randomized fashion, contrasting the responses of equivalent numbers of patients randomized to 2 experimental arms and the control arm of the study 3. to correlate the bioimpedance findings with concurrently derived, serial assessments of limb volume Recent advances in the medical understanding of the biological processes of lymphatic development and repair suggest that these mechanisms may be able to be manipulated to enhance the regenerative responses in the lymphatic vasculature following injury. Breast cancer-associated lymphedema is a model of such an acquired form of lymphatic vasculature insufficiency. Clinically, this poses a substantial clinical problem. It is estimated at 1woman in 4 who survives a breast cancer intervention will develop lymphedema, often progressively. The appearance of lymphedema has documented adverse effects on physical and psychologically well-being. New insights into lymphatic repair suggest that such mechanisms can be employed in a prophylactic fashion to forestall or eliminate the development of lymphedema. This proposal investigates this hypothesis in a prospective fashion, using a randomized trial design in 80 patients enrolled at the time of breast cancer surgery. If the investigation documents a beneficial effect of preventive measures, it could have a profound impact on subsequent breast cancer care. These measures are simple and cost-effective and, could help to eliminate the impact of a substantial detractor to the improved longevity and health that breast cancer survivors otherwise may expect to enjoy.

Interventions

DEVICEFlexitouch

A standard of care intermittent pneumatic compression device (aka, lymphedema pump)

DEVICEClass 1 compression garment

Manual lymphatic drainage therapy to provide lymphatic massage, using a Class 1 compression garment supporting the arm during heavy exercise or where the risk of trauma maybe increased (ie, flight, elevation, etc).

Sponsors

Stanford University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Unilateral breast cancer * Scheduled to undergo breast surgery and axillary lymph node dissection, with or without breast conserving techniques. * Referred to the surgeons of the Stanford University Breast Cancer Program * Capacity to provide informed consent. * All experimental protocols will be reviewed and approved by the Stanford Institutional Review Board for the Protection of Human Subjects.

Exclusion criteria

* Other serious systemic illness (renal failure, hepatic dysfunction, congestive heart failure, neurological or psychological impairment) that would confound the study or impair the patients' ability to participate. * Recurrent breast cancer or other forms of pre-existing lymphedema.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy36 monthsSuccessful, serial multiple frequency bioimpedance assessment for newly developing lymphedema in the 3 study groups
Incidence of Lymphedema (Newly-developing)3 years of semi-annual follow-upIncidence of newly-developing lymphedema for each study cohort, as detected by serial multiple frequency bioimpedance spectroscopy scans for increased interstitial fluid within regional tissues.

Countries

United States

Participant flow

Recruitment details

Enrollment commenced in May 2005 and concluded 13 March 2012. Subjects were recruited from the medical clinics and Stanford University Hospital and Clinics.

Participants by arm

ArmCount
Group I
This group of patients will receive the device.
27
Group II
This group of patients will receive prophylactic MLD
24
Group III
This is the control group; they will receive no treatment
24
Total75

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyLost to Follow-up002
Overall StudyWithdrawal by Subject830

Baseline characteristics

CharacteristicGroup IIGroup IIITotalGroup I
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
2 Participants5 Participants10 Participants3 Participants
Age, Categorical
Between 18 and 65 years
22 Participants19 Participants65 Participants24 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants0 Participants3 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
22 Participants24 Participants72 Participants26 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants0 Participants1 Participants0 Participants
Race (NIH/OMB)
Asian
2 Participants3 Participants9 Participants4 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants2 Participants2 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants2 Participants2 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants1 Participants4 Participants2 Participants
Race (NIH/OMB)
White
20 Participants20 Participants57 Participants17 Participants
Sex: Female, Male
Female
24 Participants24 Participants75 Participants27 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
1 / 195 / 215 / 22
serious
Total, serious adverse events
0 / 190 / 210 / 22

Outcome results

Primary

Incidence of Lymphedema (Newly-developing)

Incidence of newly-developing lymphedema for each study cohort, as detected by serial multiple frequency bioimpedance spectroscopy scans for increased interstitial fluid within regional tissues.

Time frame: 3 years of semi-annual follow-up

ArmMeasureValue (NUMBER)
Flexitouch DeviceIncidence of Lymphedema (Newly-developing)1 participants
Manual Lymphatic Drainage (MLD)Incidence of Lymphedema (Newly-developing)5 participants
No Intervention ControlIncidence of Lymphedema (Newly-developing)5 participants
Primary

Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy

Successful, serial multiple frequency bioimpedance assessment for newly developing lymphedema in the 3 study groups

Time frame: 36 months

Population: All enrolled patients in the trial who did not withdraw or were lost to follow-up

ArmMeasureValue (NUMBER)
Flexitouch DeviceNumber of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy19 participants
Manual Lymphatic Drainage (MLD)Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy21 participants
No Intervention ControlNumber of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy22 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026